Clinical trials: Liver Diseases
Hepatic Insufficiency
Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency
To determine the pharmacokinetics of single-dose and steady-state Tipranavir/Ritonavir (TPV/r) 500/200 mg in subjects with mild to moderate hepatic insufficiency
- Trial name
- NCT02249442
- Testing
- Tipranavir (TPV), Ritonavir (r)
- Volunteers
- 24 people
- Sponsor
- Boehringer Ingelheim
Hepatocellular Carcinoma
Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) With AMT2003
The purpose of the study is to evaluate the efficacy and the safety of AMT2003 in cancer patients with advanced primary hepatocellular carcinoma The primary endpoint is best overall response rate within 20 weeks after registration
- Trial name
- NCT00405873
- Testing
- AMT2003
- Where
- 2 sites in Germany
- Volunteers
- 73 people
- Sponsor
- Auron Healthcare GmbH
Diphtheria, Tetanus
Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants
The purpose of this trial is to clinically confirm that the manufacturing process of the final bulk products of the investigational DTaP-IPV-HB-PRP~T vaccine is consistent.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT00404651
- Testing
- DTaP-IPV-HB-PRP~T vaccine, DTaP-HBV-IPV vaccine
- Where
- 6 sites in Mexico
- Volunteers
- 1,189 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hepatocellular Carcinoma
Surefire Precision Infusion System Registry
This project involves the collection and analysis of retrospective and prospective data on patients diagnosed with hepatocellular carcinoma (HCC) in which the Surefire Precision Infusion System was used/will used be to deliver…
- Trial name
- NCT02967523
- Testing
- DEB-TACE with Surefire Precision Infusion System
- Where
- 10 sites in United States
- Volunteers
- 111 people
- Sponsor
- Surefire Medical, Inc.
Carcinoma, Hepatocellular
Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)
The primary objective of this study is to assess the safety and tolerability of subsequent systemic treatment of physician's choice (TPC) following the first-line lenvatinib treatment in unresectable hepatocellular carcinoma…
- Trial name
- NCT03433703
- Testing
- Lenvatinib
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Eisai Inc.
Hepatitis B
Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)
The purpose of this trial is to determine if there is an improvement in the immune response of older adults over 50 years of age using a modified process hepatitis B vaccine and a currently licensed hepatitis B vaccine…
- Trial name
- NCT00440531
- Testing
- Comparator: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant), Comparator: Modified Process Hepatitis B Vaccine (Experimental), Comparator: ENGERIX-B™ (currently licensed product)
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Esophageal Varices, Portal Hypertension
Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding
The main objective of this study is to determine the efficacy of early administration of Sanvar® in combination with endoscopic treatment for the control of acute variceal bleeding.
- Conditions
- Esophageal Varices, Portal Hypertension, Gastric Varices, Esophageal Bleeding
- Trial name
- NCT00331188
- Testing
- Sanvar® (vapreotide)
- Where
- 19 sites in United States
- Volunteers
- 70 people
- Sponsor
- Debiovision
Chronic Hepatitis C
Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)
This study is being done to evaluate the efficacy and safety of the drug combination grazoprevir (GZR; MK-5172) + elbasvir (EBR; MK-8742) in participants with chronic hepatitis C virus (HCV) genotype (GT) 1, 4, or 6 infection and…
- Trial name
- NCT02115321
- Testing
- Grazoprevir, Elbasvir, MK-5172A
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin
Genotype 1 CHC participants from Study SPC3649-207 with null response to prior pegylated-interferon alpha plus ribavirin will be enrolled into this 36-month extension study, designed to evaluate the long-term safety and efficacy…
- Trial name
- NCT02508090
- Where
- Puerto Rico
- Volunteers
- 10 people
- Sponsor
- Hoffmann-La Roche
Cholestasis, Intrahepatic
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus
This will be a randomized, double-blind, placebo-controlled study to assess safety and tolerability of GSK2330672 administration in subjects with primary biliary cirrhosis (PBC) and symptoms of pruritus.
- Trial name
- NCT01899703
- Testing
- GSK2330672, Ursodeoxycholic acid
- Where
- 3 sites in United Kingdom
- Volunteers
- 22 people
- Sponsor
- GlaxoSmithKline
Liver Cirrhosis
Safety and Efficacy Study of Umbilical Mesenchymal Stem Cells for Liver Cirrhosis
Liver cirrhosis and subsequent liver failure are leading causes of morbidity and mortality worldwide. Alcohol abuse and viral hepatitis are the most common causes of cirrhosis.
- Trial name
- LC (NCT01573923)
- Testing
- mesenchymal stem cells, Conventional therapy
- Where
- 6 sites in China
- Volunteers
- 320 people
- Sponsor
- Alliancells Bioscience Corporation Limited
Hepatitis C, Chronic, Hepacivirus
Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)
Study P05063 is a 3-year long-term follow-up (LTFU) study in participants previously treated with boceprevir (BOC) or narlaprevir (NAR) in a Phase 1, 2, or 3 clinical study.
- Trial name
- NCT00689390
- Testing
- Boceprevir, Narlaprevir, Peginterferon alfa-2b
- Volunteers
- 1,954 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis
Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection
This three-part, Phase 1 protocol will be the first clinical study of AB-836. Parts 1 and 2a/b will be a Phase 1a SAD/MAD of AB-836 in healthy adult subjects.
- Trial name
- NCT04775797
- Testing
- AB-836, Nucleos(t)ide Analogue
- Where
- 15 sites in Australia, Canada and 6 more
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Arbutus Biopharma Corporation
Hepatitis C, Liver Transplantation
Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C
This study will assess the rates of Sustained Virological Response following anti-viral therapy with Peg-Interferon plus Ribavirin in patients that have been liver transplanted with recurrent Hepatitis C and treated with Neoral…
- Trial name
- SUSTAIN (NCT00938860)
- Testing
- cyclosporin (Neoral), tacrolimus (Prograf)
- Where
- 45 sites in United States, Belgium and 11 more
- Volunteers
- 92 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis C Virus Infection
A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies
This is a follow-up study with no treatment and only samples being collected.
- Trial name
- NCT00872196
- Testing
- ABT-072
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hepatocellular Carcinoma
Analysis of Expression of Specific Markers and Their Prognostic Significance in Hepatocellular Carcinoma
Hepatocellular carcinoma is an aggressive disease with limited therapeutic options. Therefore, new approaches to treat this type of cancer are needed with immunotherapy potentially being one of these.
- Trial name
- NCT00911196
- Testing
- Retrospective analysis of already archived samples
- Where
- 3 sites in Taiwan, Thailand
- Volunteers
- 200 people
- Sponsor
- GlaxoSmithKline
Hepatitis C Virus
A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1
To demonstrate the effectiveness of Daclatasvir (DCV) 3 Direct Acting Antivirals (DAA) fixed dose combination in Genotype 1 Chronic Hepatitis C subjects.
- Trial name
- UNITY 4 (NCT02170727)
- Testing
- DCV/ASV/BMS-791325
- Where
- 20 sites in Russia, South Korea and 1 more
- Volunteers
- 199 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Genotype 1
Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus
The purpose of this open label study is to evaluate the safety and efficacy of daclatasvir plus pegylated interferon-alfa 2a and ribavirin in untreated hepatitis C virus in patients coinfected with HIV
- Trial name
- NCT01471574
- Testing
- Daclatasvir, Ribavirin, PEG-Interferon alfa 2a
- Where
- 86 sites in United States, Argentina and 11 more
- Volunteers
- 549 people
- Sponsor
- Bristol-Myers Squibb
Pompe Disease
An Extension Study of S-606001 in Participants With Late-onset Pompe Disease (LOPD)
The primary purpose of this study is to evaluate the long-term safety and tolerability profile of S-606001 in participants with LOPD.
- Trial name
- NCT07750990
- Testing
- S-606001, ERT
- Volunteers
- 60 people
- Sponsor
- Shionogi
Hepatitis B, Hepatitis, Viral
A Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic HBV
This is a Phase 2, open-label,randomized, multiple dose, varied administration regimen study with 2 parts (Parts A and B) in Subjects Infected with Chronic Hepatitis B Virus
- Trial name
- ACHIEVE (NCT02751996)
- Testing
- SB 9200, Tenofovir
- Where
- 17 sites in Canada, Hong Kong and 2 more
- Volunteers
- 80 people
- Sponsor
- F-star Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.